group claimed that recombinant human endostatin radiosensitized xenograthed human nasopharyngeal carcinoma in mice. Nevertheless, these inhibitors haven’t yet been clinically found in combination with radiation therapy. VEGF is among the promising targets for anticancer therapy. Neutralization of VEGF inhibited the growth of (-)-MK 801 primary tumors and metastases. Preventing VEGF with a neutralizing antibody enhanced the antitumor effects of radiation in pre-clinical studies. Yet another group reported an anti VEGF monoclonal antibody in combination with radiation resulted in tumor growth delay in mouse xenograth types. Bevacizumab is a humanized monoclonal antibody which neutralizes the VEGF ligand. Bevacizumab in combination with cytotoxic chemotherapy showed a substantial improvement in survival in patients with high level colorectal or lung cancer. Currently bevacizumab is approved for use in combination with cytotoxic chemotherapy in these diseases. the combination therapy of bevacizumab with light can be a promising strategy to enhance the antitumor effects. A clinical trial with a combination of radiation treatment plus 5 FU with bevacizumab followed closely by surgery was done and generated encouraging results in patients with locally Plastid advanced rectal cancer. the mix of radiation therapy with bevacizumab led to responses in locally advanced inoperable colorectal cancer. the addition of bevacizumab to neoadjuvant chemoradiotherapy using capecitabine triggered encouraging pathologic complete response with tolerable toxicity for locally advanced level rectal cancer. Further clinical studies have to gauge the role of combination therapy of bevacizumab with radiation or chemoradiation in patients with rectal cancers. A phase II study was performed to gauge the utilization of bevacizumab in mixture with concurrent Ivacaftor clinical trial capecitabine and radiation therapy accompanied by preservation gemcitabine and bevacizumab for patients with locally high level pancreatic cancer. The median progression free survival time and the median overall survival were similar to the results obtained in previous RTOG studies with traditional chemoradiotherapy. this result suggests that the addition of bevacizumab doesn’t improve the efficiency of traditional chemoradiotherapy in patients with locally advanced pancreatic cancer. Currently, many clinical studies using combination treatment of bevacizumab with radiation or chemoradiation are constant in patients with other malignant tumors such as glioblastoma or head and neck cancers. DC101 is just a VEGFR2 antibody, and it was reported to reduce the radiation dose necessary to control tumor types. DC101 in conjunction with light confirmed a synergistic effect when irradiation was performed several days ather the administration of DC101.